Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin, Thrombosis Research, vol.146, pp.113-118, 2016. ,
Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis, Blood, vol.121, pp.2821-2827, 2013. ,
Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons, European Journal of Cardio-Thoracic Surgery, vol.49, pp.682-689, 2016. ,
Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives, Blood, vol.117, pp.2054-2060, 2011. ,
Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay, Thrombosis and Haemostasis, vol.116, pp.452-460, 2016. ,
Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass, The Annals of Thoracic Surgery, vol.74, pp.1589-1595, 2002. ,
Protamine inhibits tissue factor-initiated extrinsic coagulation, British Journal of Haematology, vol.115, pp.392-399, 2001. ,
Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist, European Journal of Pharmacology, vol.635, pp.165-170, 2010. ,
A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass, Anesthesia and Analgesia, vol.115, pp.1273-1278, 2012. ,
First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action, European Journal of Clinical Pharmacology, vol.72, pp.1041-1050, 2016. ,
, Chest, vol.133, pp.141-159, 2008.
Protamine: a review of its toxicity, Anesthesia and Analgesia, vol.64, pp.348-361, 1985. ,
Heparinbinding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice, Translational Research, vol.177, p.10, 2016. ,
, Cardiopulmonary bypass model in the rat: a new minimal invasive model with a low flow volume. Interactive Cardiovascular and Thoracic Surgery, vol.14, pp.642-644, 2012.
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nature Medicine, vol.19, pp.446-451, 2013. ,
Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery. A randomised clinical trial, vol.116, pp.251-261, 2016. ,
Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation, Blood, vol.114, pp.1658-1665, 2009. ,
Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa, Blood, vol.119, pp.2187-2195, 2012. ,
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications, Blood, vol.107, pp.2346-2353, 2006. ,
Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants, Science Translational Medicine, vol.6, pp.260-150, 2014. ,
The toxicology of heparin reversal with protamine: past, present and future, Expert Opinion on Drug Metabolism & Toxicology, vol.12, pp.897-909, 2016. ,